Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#3790 Pancreatic neuroendocrine tumors (pNETs) in French VHL mutation carriers – A nationwide retrospective study with genotype-phenotype correlations

Introduction: Von Hippel-Lindau disease (VHL) is a rare inheritable syndrome predisposing to pancreatic neuroendocrine tumors (pNETs). The natural history of VHL-related pNETs is ill-known.

Conference:

Presenting Author:

Authors: Muller M, Hammel P, Sauvanet A, Couvelard A, Vullierme M,

Keywords: hereditary neoplastic syndrome, von Hippel-Lindau disease, VHL gene, pancreatic neuroendocrine tumor,

#2100 OPERA: Observational Study of Perception of Information and Quality of Life in Patients with Neuroendocrine Tumors Starting Lanreotide – Study Design

Introduction: Information provided to patients about burden and treatment of neuroendocrine tumors (NETs) may ease treatment adherence, outpatient monitoring, and improve quality of life (QoL), but can also cause anxiety. Data on how to individually adapt materials are insufficient and mainly derived from clinical trials.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Gueguen D, Hammel P,

Keywords: patients perception of information, QoL, lanreotide,

#1901 Portal Hypertension-Related Digestive Hemorrhage in Patients with Pancreatic Neuroendocrine Tumors

Introduction: Pancreatic neuroendocrine tumors (pNET) can cause portal hypertension (PHT)

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: MULLER N

Authors: Muller N, Zappa M, Hammel P, De Mestier L, Laurent L,

Keywords: portal hypertension,

#1351 Sunitinib (SU) in Patients with Advanced, Progressive Pancreatic Neuroendocrine Tumors (pNET): Final Overall Survival (OS) Results from a Phase III Randomized Study Including Adjustment for Crossover

Introduction: This pivotal, Phase 3, double-blind study of SU in patients (pts) with advanced, progressive pNETs met its primary endpoint with median progression-free survival of 11.4 months (mo) for SU vs 5.5 mo for placebo (PBO; HR=0.42; 95% CI 0.26–0.66; p

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Raymond E

Authors: Raymond E, Niccoli P, Castellano D, Valle J, Hammel P,

Keywords: sutent, OS,